DOI QR코드

DOI QR Code

Interferon Apha 2b for Treating Patients with JAK2V617F Positive Polycythemia Vera and Essential Thrombocytosis

  • Zhang, Zhi-Rong (Department of Hematology, Affiliated Hospital of Taishan Medical University) ;
  • Duan, Yan-Chao (Department of Hematology, Affiliated Hospital of Taishan Medical University)
  • Published : 2014.02.28

Abstract

Objective: To investigate interferon (IFN) alpha 2 b for treating patients with JAK2V617F positive polycythemia vera (PV) and essential thrombocytosis (ET). Methods: Interferon alpha 2 b was used to treat patients with JAK2V617F positive PV and ET. In control group, hydroxyurea was used. Endpoint of study was to compare rates of hematological and molecular remission. Results: Patients in the interferon alpha 2 b group achieved higher rates of hematologic and molecular remission than patients in the hydroxyurea group, with a lower incidence of thrombosis. Conclusion: Compared with hydroxyurea, interferon alpha 2 b could reduce JAK2V617F load for patients with PV and ET, and achieve higher molecular remission, improve treatment efficacy and reduce complications.

Keywords

Polycythemia vera;essential thrombocytosis;JAK2V617F mutation;Interferon;alpha 2 b

References

  1. Eickelberg O, Pansky A, Koehler E, et al (2001). Molecular mechanisms of TGF- (beta) antagonism by interferon (gamma) and cyclosporine A in lung fibroblasts. FASEB J, 15, 797-806. https://doi.org/10.1096/fj.00-0233com
  2. Rizza P, Moretti F, Belardelli F et al (2010). Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity. Autoimmunity. 43, 204-9 https://doi.org/10.3109/08916930903510880
  3. Wang Q, Miyakawa Y, Fox N, et al (2000). Interferonalpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood, 96, 2093-9.
  4. Zhao YH, Wang T, Yu GF, et al (2013). Anti-proliferation effects of interferon on gastric cancer cells. Asian Pac J Cancer Prev, 14, 5513-8. https://doi.org/10.7314/APJCP.2013.14.9.5513
  5. Dai CH, Price JO, Brunner T, et al (1998). Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis. Blood, 91, 1235-42.
  6. Dirican A, Kucukzeybek Y, Erten C, et al (2013). Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha. Asian Pac J Cancer Prev, 14, 2101-5. https://doi.org/10.7314/APJCP.2013.14.3.2101
  7. Guo Y, Wang G, Gao WW, et al (2012). Induction of apoptosis in glioma cells and upregulation of Fas expression using the human interferon gene. Asian Pac J Cancer Prev, 13, 2837-40. https://doi.org/10.7314/APJCP.2012.13.6.2837
  8. Hasselbalch HC (2011). A new era for IFN-$\alpha$ in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol, 4, 637-55. https://doi.org/10.1586/ehm.11.63
  9. Kiladjian JJ, Cassinat B, Chevret S, et al (2008). Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood, 112, 3065-72. https://doi.org/10.1182/blood-2008-03-143537
  10. Laljee RP, Muddaiah S, Salagundi B, et al (2013). Interferon stimulated gene-ISG15 is a potential diagnostic biomarker in oral squamous cell carcinomas. Asian Pac J Cancer Prev, 14, 1147-50. https://doi.org/10.7314/APJCP.2013.14.2.1147
  11. Larsen TS, Pallisgaard N, Moller MB, et al (2007). The JAK2 V617F alleleburden in essential thrombocythemia, polycythemia vera and primary myelofi-brosis - impact on disease phenotype. Eur J Haematol, 79, 508-15. https://doi.org/10.1111/j.1600-0609.2007.00960.x
  12. Quintas-Cardama A, Abdel-Wahab O, Manshouri T, et al (2013). Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon $\alpha$-2a. Blood, 122, 893-901. https://doi.org/10.1182/blood-2012-07-442012
  13. Bai J, Xue YP, Zhang L, et al (2011). Interferon-alpha-2b Induces Molecular Responses of Patients with Polycythemia Vera and Its Post-polycythemic Myelofibrosis. J Exp Haematol, 19, 444-9.
  14. Barbui T, Finazzi MC, Finazzi G, et al (2012). Front-line therapy in polycythemia vera and essential thrombocythemia. Blood Rev, 26, 205-11. https://doi.org/10.1016/j.blre.2012.06.002
  15. Barosi G, Birgegard G, Finazzi G, et al (2009). Response criteria for essential thrombocythemia and poly-cythemia vera: result of a European Leukemia Net consensus conference. Blood, 113, 4829-33. https://doi.org/10.1182/blood-2008-09-176818
  16. Chawla-Sarkar M, Lindner DJ, Liu YF, et al (2003). Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis, 8, 237-49. https://doi.org/10.1023/A:1023668705040

Cited by

  1. Acquired JAK-2 V617F Mutational Analysis in Pakistani Patients with Essential Thrombocythemia vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.7327
  2. Clinico-Hematological Profile and Risk Stratification in Patients with Essential Thrombocythemia: Experience from Pakistan vol.16, pp.17, 2015, https://doi.org/10.7314/APJCP.2015.16.17.7659
  3. Somatic JAK-2 V617F Mutational Analysis in Polycythemia Rubra Vera: a Tertiary Care Center Experience vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.1053
  4. Clinico-Epidemiological Profile of Patients with Polycythaemia Rubra Vera - a Five Year Experience from a Tertiary Care Center vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.1531